Neuroblastoma Market Report and Forecast 2024-2032

Neuroblastoma Market Outlook

The neuroblastoma market size is expected to grow at a CAGR of 2.4% during the forecast period of 2024-2032, driven by the increasing incidence of cancer and rising preference for personalised medicine across the major markets.

Neuroblastoma Market Overview

Neuroblastoma is an extracranial tumor, originating from neural crest progenitor cells. It has a high prevalence in children. 37% of the overall patients are infants, and around 90% of the patients are younger than 5 years of age. The United States witnesses around 650 new cases annually, with a prevalence of 1 case per 7,000 live births.

Neuroblastoma accounts for 15% of the overall pediatric cancers. Consequently, effective treatment has been a major area of attention amongst scientists, propelling the neuroblastoma market share. While the disease can occur anywhere along the sympathetic nervous system, it majorly arises in the adrenal glands. With heterogeneity in tumor grade, stage and location, treatment modalities vary across observation, surgical interventions, chemotherapy, radiation therapy and immunotherapy.

The neuroblastoma market growth is driven by rising preference and adoption of gene therapies to offer precise and personalized treatment to patients. In November 2023, researchers at the University of Texas developed a gene therapy to pre-treat neuroblastoma tumors by expanding blood vessels surrounding a tumor. The potential treatment can be used to enhance the efficacy of drugs to regress tumor size.

Neuroblastoma Market Trends

Neuroblastoma Market Segmentation

Market Breakup by Diagnosis

• MIBG Scan

• Imaging

• Biopsy

The market segmentation by diagnosis includes MIBG scan, imaging, and biopsy. MIBG (Metaiodobenzylguanidine) scan is a nuclear medicine imaging technique that helps in tumor visualization throughout the body using a special camera. Imaging techniques include MRI, CT scans and ultrasounds. Biopsy helps in confirming the presence of cancerous cells and provides an insight into tumor type and characteristics.

Market Breakup by Treatment

• Medication

• Surgery

• Chemotherapy

• Radiation Therapy

• Stem Cell Transplantation

• Immunotherapy

• Monoclonal Antibody Treatment

To meet the rising neuroblastoma market demand, the market segmentation addresses the treatment landscape as well. It includes medication, surgery, chemotherapy, radiation therapy, stem cell transplantation, immunotherapy, and monoclonal antibody treatment. It varies based on grade, size, and location of tumor.

Market Breakup by End Users

• Hospitals

• Specialty Clinics

• Surgical Centers

• Diagnostic Centers

• Others

Market breakup by end users constitutes hospitals, specialty clinics, surgical centers, and diagnostic centers among others. Hospitals are the most prominent alternative of tumor detection amongst patients.

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

• China

The neuroblastoma market report covers all major markets in the regional breakup. It includes United States, EU-4 (Germany, France, Italy, and Spain), United Kingdom, Japan as well as China. United States leads the market share, owing to its well-developed infrastructure along with the presence of several key healthcare and pharmaceutical players in the region. Asia Pacific is deemed to witness substantial growth in the forecast period, which can be attributed to increasing investments to improve the healthcare infrastructure.

Neuroblastoma Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Eli Lilly and Company

• Bayer AG

• GE Healthcare

• Beckman Coulter Inc

• bioMerieux

• BD Biosciences

• Lonza Biologics Ltd

• Sanofi S.A.

• Pfizer Inc.

• Cellectar Biosciences

• Baxter International Inc.

• APEIRON Biologics AG

• United Therapeutics Corporation

• Sartorious AG

• MacroGenics, Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

Key Queries Solved in the Neuroblastoma Market Report

• How has the neuroblastoma market performed so far and how is it expected to perform in the coming years?
• What are the major market trends influencing the market? 
• What are the market's major drivers, opportunities, and restraints? 
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to experience expedited growth during the forecast period? 
• How does the prevalence and incidence of neuroblastoma affect the market landscape?
• How does the rise in the geriatric population impact the neuroblastoma market value?
• What treatment type of neuroblastoma will dominate the market share? 
• Which diagnostic method is expected to have a high market value in the coming years?
• How will the ongoing clinical trials impact the market value during the forecast period? 
• What are the factors driving regional disparities in neuroblastoma treatment and outcomes? 
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?